| Scorecard |
|---|
|
4 / 5 Stars
|
|
Lipper
5
4
4
3
4
|
|
Zacks Investment Research
1
(Strong Buy)
|
|
Standard & Poor's
4 / 5 Stars
|
|
TheStreet.com
A
(Buy)
|
Fund Holdings
Asset Allocation
| % Long | % Short | % Net | |
|---|---|---|---|
| Cash | 3.18 | 0.0 | 3.18 |
| Stocks | 95.71 | 0.0 | 95.71 |
| Bonds | 0.0 | 0.0 | 0.0 |
| Other | 0.0 | 0.0 | 0.0 |
| Foreign Bonds | 0.0 | 0.0 | 0.0 |
| Foreign Stocks | 1.09 | 0.0 | 1.08 |
| Convertible | 0.0 | 0.0 | 0.0 |
| Preferred | 0.02 | 0.0 | 0.02 |
Updated 03.31.2013
Top 10 Holdings
Performance as of 04.30.2013
Portfolio as of 03.31.2013
| Ticker | YTD Return % | % Net Assets | |
|---|---|---|---|
| Amgen Inc | AMGN | 21.82 | 14.92 |
| Gilead Sciences Inc | GILD | 36.53 | 14.56 |
| Celgene Corporation | CELG | 48.67 | 7.42 |
| Biogen Idec Inc | BIIB | 46.43 | 6.27 |
| Alexion Pharmaceuticals, Inc. | ALXN | 3.13 | 3.74 |
| Regeneron Pharmaceuticals, Inc. | REGN | 38.71 | 3.58 |
| Vertex Pharmaceuticals | VRTX | 83.37 | 3.47 |
| Biomarin Pharmaceutical, Inc. | BMRN | 29.43 | 2.99 |
| Onyx Pharmaceuticals, Inc. | ONXX | 19.29 | 2.63 |
| Medivation, Inc. | MDVN | 0.06 | 1.84 |
